XML 33 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Operating Activities    
Net loss $ (3,906) $ (25,350)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 714 995
Depreciation and amortization 764 1,156
Gain on sale of Aptevo BioTherapeutics (14,338)  
Loss on extinguishment of debt 2,104  
Non-cash interest expense and other 137 310
Changes in operating assets and liabilities:    
Royalty receivable (288)  
Accounts receivable   (2,158)
Inventories   (5,182)
Prepaid expenses and other current assets 499 2,270
Operating lease right of use asset 496 428
Accounts payable, accrued compensation and other liabilities (3,239) (1,246)
Long-term operating lease liability (470) (607)
Changes in assets and liabilities held for sale 1,719  
Sales rebates and discounts   (351)
Net cash used in operating activities (15,808) (29,735)
Investing Activities    
Cash received from sale of Aptevo BioTherapeutics 28,120  
Purchases of property and equipment   (153)
Net cash (used in) provided by investing activities 28,120 (153)
Financing Activities    
Payment of long-term debt, including exit and other fees (22,104)  
Proceeds of issuance of common stock, warrants, and pre-funded warrants, net   20,297
Proceeds from the exercise of pre-funded warrants   21
Payment of tax liability for vested equity awards   (58)
Net cash provided by (used in) financing activities (22,104) 20,260
Decrease in cash, cash equivalents, and restricted cash (9,792) (9,628)
Cash, cash equivalents, and restricted cash at beginning of period 19,946 38,083
Cash, cash equivalents, and restricted cash at end of period $ 10,154 $ 28,455